| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 104,514 | 135,381 | ||
| Marketable securities (note 5) | 357,754 | 352,164 | ||
| Other receivables | 812 | 1,097 | ||
| Prepaid expenses and other current assets | 17,057 | 11,610 | ||
| Total current assets | 480,137 | 500,252 | ||
| Marketable securities, long-term (note 5) | 92,988 | 137,297 | ||
| Operating lease right-of-use asset, net (note 6) | 6,960 | 7,290 | ||
| Property, plant and equipment, net | 8,887 | 9,205 | ||
| Deferred tax assets | 11,750 | 11,049 | ||
| Prepaid expenses, long-term | 7,114 | 9,188 | ||
| Total assets | 607,836 | 674,281 | ||
| Accounts payable and accrued liabilities (note 7) | 36,840 | 31,588 | ||
| Operating lease liability (note 6) | 1,495 | 1,459 | ||
| Total current liabilities | 38,335 | 33,047 | ||
| Operating lease liability, long-term (note 6) | 6,832 | 7,256 | ||
| Other liabilities, long-term | 3,158 | - | ||
| Total liabilities | 48,325 | 40,303 | ||
| Common shares, without par value unlimited shares authorized issued and outstanding 77,120,168 (december 31, 2024 - 76,416,086) (note 8) | 1,475,371 | 1,469,196 | ||
| Additional paid-in capital | 223,782 | 213,892 | ||
| Accumulated deficit | -1,140,119 | -1,049,223 | ||
| Accumulated other comprehensive income (loss) | 477 | 113 | ||
| Total shareholders' equity | 559,511 | 633,978 | ||
| Total liabilities and shareholders equity | 607,836 | 674,281 | ||
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)